PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
NCT ID: NCT00107848
Last Updated: 2014-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
280 participants
INTERVENTIONAL
2004-10-31
2005-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open Label Study of FT218 in Subjects With Narcolepsy
NCT04451668
A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy
NCT00424931
Modafinil to Treat Fatigue in Post-Polio Syndrome
NCT00067496
Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
NCT02720744
Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy
NCT01067222
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Modafinil
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A boy or girl aged 6 through 16 years (at the start of the previous double blind study), inclusive, who participated in study C1538/3027/NA/MN or C1538/3028/AP/MN
* Have a diagnosis (as established in the previous double blind study) of narcolepsy (or presumed narcolepsy) or OSAHS according to the criteria established by the International Classification of Sleep Disorders (ICSD) manual of the American Academy of Sleep Medicine (AASM)
* Continue to be in good health as determined by a medical and psychiatric history, ECGs, physical examination findings, serum chemistry, hematology, and urinalysis
* Have blood pressure values greater than those for the 5th percentile and less than the 95th percentile on the National High Blood Pressure Education Program guidelines for blood pressure levels for boys and girls ages 6 through 16 years
* Girls who are post menarche or sexually active who have a negative urine pregnancy test at the screening/baseline visit, must be using a medically acceptable method of birth control, and must agree to continued use of this method for the duration of the study (and for 30 days after participation in the study). Acceptable methods of birth control include: barrier method with spermicide; steroidal contraceptives (oral, topical \[patch\], implanted, and injected) in conjunction with a barrier method; intrauterine device (IUD); or abstinence
* No positive urine drug screen (UDS) for any illicit drug or alcohol (ethanol) at baseline visit, unless a false positive is suspected, in which case the UDS will be repeated. If the patient has a positive drug screen for methylphenidate or amphetamine at screening, the patient must have a negative UDS after a washout period and prior to baseline.
* Have a parent or legal guardian who is willing to participate in the study
Exclusion Criteria
* Have a past or present seizure disorder (except history of a single febrile seizure), a history of psychosis, or of clinically significant head trauma (eg, brain damage) or past neurosurgery
* Have a history of suicide attempt, or are at suicidal risk
* A clinically significant drug sensitivity to stimulants such as amphetamine, dextroamphetamine, methylphenidate, or pemoline; and modafinil or any of its components
* Any disorder that could interfere with drug absorption, distribution, metabolism, or excretion (including previous gastrointestinal surgery)
* Active, clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematologic, neoplastic, endocrine, neurologic, immunodeficiency, pulmonary, or other major clinically significant disorder/disease
* Any clinically significant deviation from the normal range(s) in the ECG or physical examination findings, or clinical laboratory (ie, hematology, serum chemistry, urinalysis) test results at the screening/baseline visit
* Absolute neutrophil count (ANC) below the lower limit of normal at the baseline visit (NOTE: If the ANC is below the lower limit of normal at the baseline visit, the medical monitor will be consulted for continued eligibility in the study.)
* A seated pulse outside the range of 60 through 115 bpm after resting for 5 minutes
* A total daily intake of more than 500 mg of caffeine per day (eg, approximately ten 12 ounce caffeinated sodas, 5 cups of coffee or tea, or about 25 ounces of chocolate per day) within 1 week of the baseline visit
* Pregnant or lactating/nursing; any child who becomes pregnant during the study will be withdrawn.
6 Years
16 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cephalon
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Robert Doekel, Jr., M.D.
Birmingham, Alabama, United States
Chris M. Makris, M.D.
Birmingham, Alabama, United States
Barbara Harris, Ph.D.
Phoenix, Arizona, United States
Derek Loewy, Ph.D.
Tucson, Arizona, United States
Joseph McCarty, M.D.
Fort Smith, Arkansas, United States
Samuel Boellner, M.D.
Little Rock, Arkansas, United States
Julie Thompson-Dobkin, D.O.
Huntington Beach, California, United States
Mark Buchfuhrer, M.D.
Long Beach, California, United States
Yury Furman, M.D.
Los Angeles, California, United States
Stuart Menn, M.D.
Palm Springs, California, United States
Lawrence Sher, M.D.
Rolling Hills Estates, California, United States
Milton K. Erman, M.D.
San Diego, California, United States
Jed Black, M.D.
Stanford, California, United States
Edward O'Malley
Norwalk, Connecticut, United States
Elias H. Sarkis
Gainesville, Florida, United States
Americo Padilla, M.D.
Miami, Florida, United States
Martin A. Cohn, M.D.
Naples, Florida, United States
D. Alan Lankford, Ph.D.
Atlanta, Georgia, United States
Gary Montgomery, M.D.
Atlanta, Georgia, United States
Jerry Silverboard, M.D.
Atlanta, Georgia, United States
Charles Wells, Jr., M.D.
Macon, Georgia, United States
Joel Greenberg
Savannah, Georgia, United States
Robert M. Cohen
Stockbridge, Georgia, United States
Stephen H. Sheldon, D.O., FAAP
Chicago, Illinois, United States
Michael Kohrman, M.D.
Chicago, Illinois, United States
James Cook, M.D.
Danville, Indiana, United States
William Leeds, D.O.
Topeka, Kansas, United States
Karen Waters, M.D.
Louisville, Kentucky, United States
Margaret Ann Springer, M.D.
Shreveport, Louisiana, United States
Helene A. Emsellem, M.D.
Chevy Chase, Maryland, United States
Marc Raphaelson
Frederick, Maryland, United States
George Zureikat, M.D.
Flint, Michigan, United States
John Harsh, Ph.D., DABSM
Hattiesburg, Mississippi, United States
William Torch, M.D., MS
Reno, Nevada, United States
Kathleen Ryan, M.D.
Mount Laurel, New Jersey, United States
Monroe Karetzky, M.D.
Newark, New Jersey, United States
Lee Brooks, M.D.
Princeton, New Jersey, United States
Marc Seelagy, M.D.
Trenton, New Jersey, United States
Gary Zammit, M.D.
New York, New York, United States
Carol Rosen
Cleveland, Ohio, United States
Michael Neeb, Ph.D.
Toledo, Ohio, United States
Ramalinga Reddy
Toledo, Ohio, United States
William C. Orr, Ph.D.
Oklahoma City, Oklahoma, United States
Jorg Pahl, M.D.
Oklahoma City, Oklahoma, United States
Judith Owens, M.D., MPH
Providence, Rhode Island, United States
Richard Bogan, M.D., FCCP
Columbia, South Carolina, United States
Julie Jacques, D.O.
Morristown, Tennessee, United States
John Hudson, M.D.
Austin, Texas, United States
David Sperry, M.D.
Dallas, Texas, United States
Todd J. Swick, M.D.
Houston, Texas, United States
Jerry J. Tomasovic, M.D.
San Antonio, Texas, United States
Radiant Research, Salt Lake City
Salt Lake City, Utah, United States
James M. Ferguson, M.D.
Salt Lake City, Utah, United States
James Perlstrom
Fairfax, Virginia, United States
Robert J. Reichler
Seattle, Washington, United States
Adam Moscovitch, M.D.
Calgary, Alberta, Canada
Manisha Witmans
Edmonton, Alberta, Canada
Lawrence Reinish
Parry Sound, Ontario, Canada
Leonid Kayumov, M.D.
Scarborough Village, Ontario, Canada
Mortimer Mamelak, M.D.
Toronto, Ontario, Canada
Colin Shapiro, Ph.D.
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C1538/3029/ES/MN-Open label
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.